Dean Wilkie
- Hepatology top 1%
- Hepatocellular Carcinoma Treatment and Prognosis 2
- Cancer Research top 5%
- Protease and Inhibitor Mechanisms 3
-
- Cancer Mechanisms and Therapy 2
- Oncology top 5%
- Peptidase Inhibition and Analysis 4
- Otorhinolaryngology top 5%
-
- Angiogenesis and VEGF in Cancer 3
- PI3K/AKT/mTOR signaling in cancer 2
-
- Knee injuries and reconstruction techniques 2
-
- Osteoarthritis Treatment and Mechanisms 2
Dean Wilkie
16 papers receiving 2.5k citations
Hit Papers
Peers
Comparison fields: 5 of 104
- Hepatology 620
- Cancer Research 560
- Pathology and Forensic Medicine 503
- Oncology 705
- Otorhinolaryngology 85
Countries citing papers authored by Dean Wilkie
This map shows the geographic impact of Dean Wilkie's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Dean Wilkie with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Dean Wilkie more than expected).
Fields of papers citing papers by Dean Wilkie
This network shows the impact of papers produced by Dean Wilkie. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Dean Wilkie. The network helps show where Dean Wilkie may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Dean Wilkie, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2015 | 29 | |
| 2 | 2015 | 23 | |
| 3 | 2014 | 9 | |
| 4 | 2013 | 206 | |
| 5 | 2009 | 62 | |
| 6 | 2007 | 134 | |
| 7 | 2007 | 183 | |
| 8 | Sorafenib Blocks the RAF/MEK/ERK Pathway, Inhibits Tumor Angiogenesis, and Induces Tumor Cell Apoptosis in Hepatocellular Carcinoma Model PLC/PRF/5breakdown → | 2006 | 1273 |
| 9 | 2006 | 388 | |
| 10 | Baseline phosphorylated ERK levels in renal cell carcinoma patients from a phase II study of BAY 43–9006. | 2004 | 2 |
| 11 | 2004 | 2 | |
| 12 | 1997 | 82 | |
| 13 | Enrichment of collagen and gelatin degrading activities in the plasma membranes of human cancer cells. | 1987 | 58 |
| 14 | 1987 | 50 | |
| 15 | 1986 | 3 | |
| 16 | Diversity of human pancreatic cancer cell proteinases: role of cell membrane metalloproteinases in collagenolysis and cytolysis. | 1985 | 30 |
About Dean Wilkie
Dean Wilkie is a scholar working on Immunology and Allergy, Cancer Research, Hepatology, Rheumatology and Genetics, having authored 16 papers that have together received 2.5k indexed citations. Recurring topics across this work include Peptidase Inhibition and Analysis (4 papers), Protease and Inhibitor Mechanisms (3 papers), Angiogenesis and VEGF in Cancer (3 papers), Cancer Mechanisms and Therapy (2 papers), Hepatocellular Carcinoma Treatment and Prognosis (2 papers), Knee injuries and reconstruction techniques (2 papers), Osteoarthritis Treatment and Mechanisms (2 papers) and PI3K/AKT/mTOR signaling in cancer (2 papers). The work is most often cited by research in Hepatology (620 citations), Cancer Research (560 citations), Pathology and Forensic Medicine (503 citations), Oncology (705 citations) and Otorhinolaryngology (85 citations). Dean Wilkie has collaborated with scholars based in United States, Germany and Canada. Frequent co-authors include Scott M. Wilhelm, Mark Lynch, Charles Chen, Yichen Cao, Christopher Carter, Xiaomei Zhang, Li Liu, Cedo M. Bagi, Pamela A. Trail and Jalila Adnane. Their work appears in journals such as Molecular Cancer Therapeutics, Leukemia, Cancer Chemotherapy and Pharmacology, Bone and Journal of Translational Medicine.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.